Skip to main content

Table 1 Characteristics of the randomized placebo-controlled trials considered for the guideline in episodic migraine

From: Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Study Study phase Treatment regimen Duration of treatment Participants (n) Women (%) Age range (years) Monthly migraine days (range) Preventive treatment (% using) Exclusion by preventive failure (n. of drugs/ categories)
Eptinezumab
 Dodick, 2014 [32] II 1000 mg quarterly ev 3 months 174 80–83 18–55 5–14 Not Allowed
Erenumab
 Sun, 2016 [44] II 70 mg monthly sc 3 months 483 77–83 18–60 4–14 Not allowed > 2
 STRIVE [36] III 70 mg monthly sc
140 mg monthly sc
6 months 955 85–86 18–65 4–14 2–3 > 2
 ARISE [35] III 70 mg monthly sc 3 months 577 85–86 18–65 4–14 6–7 > 2
Fremanezumab
 Bigal, 2015 [27] II 225 mg (225 mg quarterly) sc
675 mg (225 mg monthly) sc
3 months 297 85–91 18–65 8–14 27–34 > 2
 HALO EM [34] III 225 mg monthly sc
675 mg quarterly sc
3 months 875 84–86 18–70 6–14 20–21 ≥2
Galcanezumab
 Dodick, 2014 [33] II 150 mg every two weeks sc 3 months 218 82–87 18–65 4–14 Not Allowed > 2
 Skljarevski, 2018 [42] II 120 mg monthly sc
300 mg monthly sc
3 months 410 80–85 18–65 4–14 NR > 2
 EVOLVE-1 [43] III 120 mg monthly sc (240 mg ld)
240 mg monthly sc
6 months 858 83–85 18–65 4–14 Not allowed > 2
 EVOLVE-2 [51] III 120 mg monthly sc (240 mg ld)
240 mg monthly sc
6 months 922 85–86 18–65 4–14 Not allowed > 2
  1. ev: endovenous; sc: subcutaneous; ld loading dose; NR: not reported.
  2. Reported treatment regimen in the Fremanezumab study is 225 mg monthly.
  3. For the Galcanezumab study, the originally published line for EVOLVE-2 was replaced with Skljarevski, 2018. A new row was introduced for EVOLVE-2, linked to reference 51
\